Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer
DE Gerber, WC Putnam, FJ Fattah, KH Kernstine… - Clinical Cancer …, 2020 - AACR
Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer
DE Gerber, WC Putnam, FJ Fattah… - … : an official journal …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
[HTML][HTML] Concentration-dependent early anti-vascular and anti-tumor effects of itraconazole in non-small cell lung cancer
DE Gerber, WT Putnam, FJ Fattah… - … cancer research: an …, 2020 - ncbi.nlm.nih.gov
Methods: Patients who had non-small cell lung cancer planned for surgical resection were
administered 10–14 days of itraconazole 300 mg orally twice daily. Patients underwent …
administered 10–14 days of itraconazole 300 mg orally twice daily. Patients underwent …
Concentration-dependent early antivascular and antitumor effects of itraconazole in non-small cell lung cancer.
DE Gerber, WC Putnam, FJ Fattah, KH Kernstine… - 2020 - cabidigitallibrary.org
Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer.
DE Gerber, WC Putnam, FJ Fattah… - … Cancer Research: an …, 2020 - europepmc.org
Purpose Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
Concentration-dependent early antivascular and antitumor effects of itraconazole in non-small cell lung cancer
DE Gerber, WC Putnam… - Clinical Cancer …, 2020 - utsouthwestern.elsevierpure.com
Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer.
DE Gerber, WC Putnam, FJ Fattah… - … Cancer Research: an …, 2020 - europepmc.org
Purpose Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …